AU7516594A - Pre-binding of retroviral vector particles with complement components to enable the performance of human gene therapy (in vivo) - Google Patents

Pre-binding of retroviral vector particles with complement components to enable the performance of human gene therapy (in vivo)

Info

Publication number
AU7516594A
AU7516594A AU75165/94A AU7516594A AU7516594A AU 7516594 A AU7516594 A AU 7516594A AU 75165/94 A AU75165/94 A AU 75165/94A AU 7516594 A AU7516594 A AU 7516594A AU 7516594 A AU7516594 A AU 7516594A
Authority
AU
Australia
Prior art keywords
vivo
binding
enable
performance
gene therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU75165/94A
Inventor
James M Mason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU7516594A publication Critical patent/AU7516594A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU75165/94A 1993-07-28 1994-07-28 Pre-binding of retroviral vector particles with complement components to enable the performance of human gene therapy (in vivo) Abandoned AU7516594A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9894493A 1993-07-28 1993-07-28
US098944 1993-07-28
PCT/US1994/008526 WO1995003834A1 (en) 1993-07-28 1994-07-28 PRE-BINDING OF RETROVIRAL VECTOR PARTICLES WITH COMPLEMENT COMPONENTS TO ENABLE THE PERFORMANCE OF HUMAN GENE THERAPY $i(IN VIVO)

Publications (1)

Publication Number Publication Date
AU7516594A true AU7516594A (en) 1995-02-28

Family

ID=22271673

Family Applications (1)

Application Number Title Priority Date Filing Date
AU75165/94A Abandoned AU7516594A (en) 1993-07-28 1994-07-28 Pre-binding of retroviral vector particles with complement components to enable the performance of human gene therapy (in vivo)

Country Status (2)

Country Link
AU (1) AU7516594A (en)
WO (1) WO1995003834A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000542A2 (en) * 1996-07-03 1998-01-08 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia
EP1052288A1 (en) * 1999-05-10 2000-11-15 Transgene S.A. Complex for transferring an anionic substance of interest into a cell
EP1052287A3 (en) * 1999-05-10 2003-07-09 Transgene S.A. Complex for transferring an anionic substance of interest into a cell

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563239A4 (en) * 1990-12-20 1994-10-12 Univ Pittsburgh A truncated interleukin-1 receptor gene for the treatment of arthritis.
EP0644946A4 (en) * 1992-06-10 1997-03-12 Us Health Vector particles resistant to inactivation by human serum.
JP3533219B2 (en) * 1992-11-09 2004-05-31 アメリカ合衆国 Targeting vector particles

Also Published As

Publication number Publication date
WO1995003834A1 (en) 1995-02-09

Similar Documents

Publication Publication Date Title
AU4528493A (en) In vivo gene therapy with intron-free sequence of interest
AU674104B2 (en) Therapeutic ribozyme compositions and expression vectors
AU5546086A (en) Non-invasive determination of mechanical characteristics in the body
AU6797094A (en) Cosmetic treatment of substrates
IL113822A0 (en) Retroviral vectors host cells containing the same and methods for the preparation of safe vectors utilizing the same
AU4636589A (en) Tissue culture antiviral processes and compositions
AU7623096A (en) Use of epinastine in the treatment of pain
AU7272196A (en) Use of hyaluronan in gene therapy
ZA945012B (en) Viral vectors and their use in gene therapy
AU3002497A (en) Treatment of human cancers with an adenovirus vector containing an interferon consensus gene
AU3517489A (en) Imidazoquinoxaline compounds and their preparation and use
SG42309A1 (en) Medical use of enzymes
AU5317794A (en) 9H-imidazo(1,2-a)benzimidazole-3-acetamide derivates, their preparation and their therapeutic application
AU7516594A (en) Pre-binding of retroviral vector particles with complement components to enable the performance of human gene therapy (in vivo)
AU2975692A (en) Expression vectors and their use in the preparation of HIV-resistant human cells for therapeutic applications
AU4043489A (en) Improvements in or relating to reducing the strength of electro-magnetic fields
AU2554595A (en) Compositions and uses thereof in the diagnosis of psoriasis
AU3608589A (en) Expression vectors for the preparation of infused proteins in microorganisms
AU2971689A (en) Tanning compositions and their use
AU639954B2 (en) Application and use of in particular magnetic vector potentials for the treatment of materials
AU6653698A (en) Use of the p-ten suppressor gene in diagnosis and treatment of cancer
AU1485197A (en) Diamines in the treatment of arrhythmia
AU6491890A (en) Use of arylalkylamides in the treatment of neurodegenerative diseases
AU7780791A (en) Neonatal human blood bank and hematopoietic or immune reconstitutions performed therewith
AU641157B2 (en) 2-imino-thiadiazoline-5-sulphonamides and their use in the treatment of glaucoma